Invention Grant
![Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors](/docs/US/2021-03-02/US10934294B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors
-
Application No.: US16001295Application Date: 2018-06-06
-
Publication No.: US10934294B2Publication Date: 2021-03-02
- Inventor: Ashok Arasappan , Jason M. Cox , John S. Debenham , Zhuyan Guo , Jiafang He , Zahid Hussain , Zhong Lai , Derun Li , Dongfang Meng , Subharekha Raghavan , Sriram Tyagarajan
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent J. Eric Thies; John C. Todaro
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D487/04 ; A61P9/00 ; A61P25/00 ; A61P13/12 ; A61P25/18
![Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors](/abs-image/US/2021/03/02/US10934294B2/abs.jpg.150x150.jpg)
Abstract:
The present invention is directed to pyrazolopyrimidine compounds of the general structural formula I: which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Public/Granted literature
- US20180354955A1 PYRAZOLOPYRIMIDINE PDE9 INHIBITORS Public/Granted day:2018-12-13
Information query
IPC分类:
